CY1112507T1 - Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β - Google Patents

Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β

Info

Publication number
CY1112507T1
CY1112507T1 CY20111101274T CY111101274T CY1112507T1 CY 1112507 T1 CY1112507 T1 CY 1112507T1 CY 20111101274 T CY20111101274 T CY 20111101274T CY 111101274 T CY111101274 T CY 111101274T CY 1112507 T1 CY1112507 T1 CY 1112507T1
Authority
CY
Cyprus
Prior art keywords
human
particular parts
specialized
parts specialized
antibody molecule
Prior art date
Application number
CY20111101274T
Other languages
English (en)
Inventor
Alastair D G Lawson
Andrew G Popplewell
Original Assignee
Ucb Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma S.A. filed Critical Ucb Pharma S.A.
Publication of CY1112507T1 publication Critical patent/CY1112507T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

Η εφεύρεση αφορά ένα μόριο αντισώματος, που έχει ειδικότητα για αντιγονικούς προσδιοριστές της ΙL-1β, θεραπευτικές χρήσεις του μορίου αντισώματος και μεθόδους για την παραγωγή του εν λόγω μορίου αντισώματος.
CY20111101274T 2003-02-13 2011-12-21 Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β CY1112507T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0303337.0A GB0303337D0 (en) 2003-02-13 2003-02-13 Biological products
EP04708808A EP1597282B1 (en) 2003-02-13 2004-02-06 Antibody molecules having specificity for human il-1 beta

Publications (1)

Publication Number Publication Date
CY1112507T1 true CY1112507T1 (el) 2015-12-09

Family

ID=9952969

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101274T CY1112507T1 (el) 2003-02-13 2011-12-21 Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β

Country Status (26)

Country Link
US (2) US7608694B2 (el)
EP (2) EP1597282B1 (el)
JP (2) JP4668896B2 (el)
KR (1) KR20050099509A (el)
CN (1) CN1745103A (el)
AR (1) AR043159A1 (el)
AT (1) ATE525397T1 (el)
AU (1) AU2004210776B2 (el)
BR (1) BRPI0407233A (el)
CA (1) CA2515474C (el)
CL (1) CL2004000259A1 (el)
CY (1) CY1112507T1 (el)
DK (1) DK1597282T3 (el)
EA (1) EA200501286A1 (el)
EC (1) ECSP056014A (el)
ES (1) ES2373953T3 (el)
GB (1) GB0303337D0 (el)
IS (1) IS8013A (el)
MX (1) MXPA05007392A (el)
NO (1) NO20054223L (el)
PE (1) PE20040947A1 (el)
PL (1) PL378412A1 (el)
PT (1) PT1597282E (el)
SI (1) SI1597282T1 (el)
TW (1) TW200505942A (el)
WO (1) WO2004072116A2 (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
KR20070047327A (ko) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. 항-ｃｄ154 항체
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
MX348154B (es) 2005-06-21 2017-05-30 Xoma (Us) Llc Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
CN102861332A (zh) * 2005-10-26 2013-01-09 诺瓦提斯公司 IL-1β化合物的新用途
BRPI0619595B8 (pt) 2005-12-09 2022-12-13 Ucb Pharma Sa anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
JP5645409B2 (ja) 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法
MX2009010120A (es) 2007-03-22 2009-10-19 Ucb Pharma Sa Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
BRPI0820099A2 (pt) 2007-12-07 2020-11-24 Zymogenetics, Inc anticorpo isolado ou fragmento de anticorpo, composição farmacêutica, e, uso de um anticorpo ou fragmento de anticorpo
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
MX2010011761A (es) * 2008-04-28 2010-11-30 Kalobios Pharmaceuticals Inc Anticuerpos para el factor que estimula la colonia del granulocito-macrofago.
CA2735940A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for treating or preventing il-1.beta. related diseases
SG173620A1 (en) * 2009-02-17 2011-09-29 Ucb Pharma Sa Antibody molecules having specificity for human ox40
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
BR112012006670B8 (pt) 2009-09-24 2022-03-03 Ucb Pharma Sa Célula bacteriana gram-negativa recombinante, e, método para produzir uma proteína recombinante
BR112012007365A2 (pt) * 2009-10-15 2016-11-22 Abbott Lab proteínas de ligação à il-1
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
MX337586B (es) 2010-05-07 2016-03-11 Xoma Us Llc Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta.
LT2571532T (lt) 2010-05-14 2017-08-10 Abbvie Inc. Il-1 surišantys baltymai
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
MA34907B1 (fr) 2011-01-14 2014-02-01 Ucb Pharma Sa Molécules d'anticorps se liant à il-17a et il-17f
ES2659155T3 (es) 2011-07-13 2018-03-14 Ucb Biopharma Sprl Cepa hospedante bacteriana que expresa DSBC recombinante
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
PL2814843T3 (pl) 2012-02-13 2020-11-16 Agency For Science, Technology And Research Ludzkie przeciwciała monoklonalne neutralizujące IL-β
WO2013157102A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
WO2014011955A2 (en) 2012-07-12 2014-01-16 Abbvie, Inc. Il-1 binding proteins
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
JP6397933B2 (ja) 2014-01-20 2018-09-26 ユーシービー バイオファルマ エスピーアールエル 固体形態の医薬組成物の再構成のための方法
GB201501613D0 (en) 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
US9560393B2 (en) * 2015-02-20 2017-01-31 Disney Enterprises, Inc. Media processing node
CN106349388B (zh) * 2015-07-17 2021-04-02 上海佳文英莉生物技术有限公司 一种促细胞程序性坏死抗体及其应用
WO2017072183A1 (en) 2015-10-27 2017-05-04 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
JP7256266B2 (ja) * 2018-11-07 2023-04-11 沢達生物医薬有限公司 ヒトＩＬ－１βに結合する抗体、その調製方法及び用途
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
CN116802211A (zh) 2020-12-07 2023-09-22 Ucb生物制药有限责任公司 针对白介素-22的抗体
MX2023006650A (es) 2020-12-07 2023-06-21 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos.
KR20240004694A (ko) 2021-05-03 2024-01-11 유씨비 바이오파마 에스알엘 항체
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN113855807A (zh) * 2021-10-25 2021-12-31 孙良丹 一种试剂在制备治疗/抑制银屑病药物中的应用
CN114524875B (zh) * 2021-11-11 2023-07-25 江苏莱森生物科技研究院有限公司 偶联IL-1β单克隆抗体的纳米硅球及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB129105A (en) 1918-07-02 1919-07-02 Alfred George Hubble Improvements in and connected with Closing Means for Milk Churns, Containers and Vessels.
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
DK0813423T3 (da) 1995-01-23 2002-07-22 Xenotech Inc Præparat til forebyggelse af osteolysis og metastase
JPH09183799A (ja) * 1995-11-06 1997-07-15 Merck Patent Gmbh ヒト化モノクローナル抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20050075488A1 (en) 2001-07-26 2005-04-07 Bright Stuart Willis Interleukin-1 beta antibodies
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products

Also Published As

Publication number Publication date
ATE525397T1 (de) 2011-10-15
KR20050099509A (ko) 2005-10-13
AU2004210776A1 (en) 2004-08-26
ECSP056014A (es) 2006-01-27
US20060228358A1 (en) 2006-10-12
NO20054223D0 (no) 2005-09-12
GB0303337D0 (en) 2003-03-19
CL2004000259A1 (es) 2005-04-15
AU2004210776B2 (en) 2011-04-07
US7608694B2 (en) 2009-10-27
DK1597282T3 (da) 2012-01-23
ES2373953T3 (es) 2012-02-10
EP2287193A1 (en) 2011-02-23
CN1745103A (zh) 2006-03-08
WO2004072116A3 (en) 2004-11-18
JP2010246553A (ja) 2010-11-04
PE20040947A1 (es) 2004-12-29
NO20054223L (no) 2005-11-08
AR043159A1 (es) 2005-07-20
BRPI0407233A (pt) 2006-01-31
IS8013A (is) 2005-09-07
CA2515474C (en) 2013-11-12
PT1597282E (pt) 2012-01-05
EA200501286A1 (ru) 2006-02-24
JP4668896B2 (ja) 2011-04-13
WO2004072116A2 (en) 2004-08-26
EP1597282B1 (en) 2011-09-21
US20100158913A1 (en) 2010-06-24
EP1597282A2 (en) 2005-11-23
MXPA05007392A (es) 2005-09-12
PL378412A1 (pl) 2006-04-03
CA2515474A1 (en) 2004-08-26
SI1597282T1 (sl) 2012-02-29
JP2007515925A (ja) 2007-06-21
TW200505942A (en) 2005-02-16
US8465744B2 (en) 2013-06-18

Similar Documents

Publication Publication Date Title
CY1112507T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β
CY1115147T1 (el) Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1119106T1 (el) Αντισωματα εναντι masp-2
TW200728466A (en) Antibody molecules having specificity for human IL-6
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1116571T1 (el) Ενωσεις φωσφορικου αμινοαλκυλο γλυκοζαμinιδιου και χρηση αυτων
CY1115730T1 (el) Θεραπευτικοι επιτοποι και χρησεις αυτων
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CY1118171T1 (el) Θεραπευτικη αντιμετωπιση της φαiνυλκετονουρiας me βη4
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
DE60220719D1 (de) Antikörper gegen das muc18-antigen
DE60333229D1 (de) VL DAb FC-FUSION
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
ATE447561T1 (de) Substituierte aryl 1,4-pyrazin derivate
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
CY1110571T1 (el) Επιλεκτικα μεσα δεσμευσης της ανθρωπινης αγγειοποιητινης-2
CY1108645T1 (el) Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri